NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Arcutis reported strong Q4 2023 financial results driven by ZORYVE® cream revenue growth and FDA approval of ZORYVE® foam.
Arcutis Biotherapeutics, Inc. reported a significant increase in total revenues for Q4 2023, driven by strong demand for ZORYVE® cream. The company also achieved FDA approval for ZORYVE® foam and anticipates a transformational year in 2024 with potential approval for roflumilast cream for atopic dermatitis.
- Q4 net product revenues for ZORYVE® cream increased by 357% compared to Q4 2022, reaching $13.5 million.
- Arcutis received FDA approval for ZORYVE® topical foam for seborrheic dermatitis in December 2023.
- The FDA has set a PDUFA action date of July 7, 2024, for roflumilast cream for atopic dermatitis.
- Arcutis' strong financial position supports investment in plaque psoriasis and seborrheic dermatitis launches and continued pipeline development.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$13.5M
Forward guidance
Arcutis anticipates a transformational year in 2024 with potential approval for roflumilast cream for atopic dermatitis.
Tailwinds
- Strong revenue growth trend reinforcing demand for new treatment options and physician adoption of ZORYVE
- Two FDA-approved products in the midst of their commercial launches
- Mid-year PDUFA action date for roflumilast cream for atopic dermatitis
- Expanding product portfolio
- Robust development pipeline
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro